Company

Cancer remains one of the world’s most significant diseases. A key challenge in the fight against cancer is that many tumours continue to grow by successfully evading the body’s own natural defence mechanism - the immune system. Scancell’s mission is to overcome this breach in our defences by developing products that stimulate the immune system to treat or prevent cancer.

The company, which was founded in 1997 as a spin-out from the University of Nottingham, has secured £8.7 million funding to date. In December 2006 Scancell sold its pipeline of direct killing monoclonal antibodies to Arana Therapeutics, an Australian biopharmaceutical company. The deal allowed Scancell to focus its efforts entirely on its innovative ImmunoBody® cancer vaccine programme.

Scancell’s first clinical candidate drug , SCIB1, is a DNA vaccine which is being developed for the treatment of melanoma and is in Phase I clinical trials.

In September 2008 Scancell became a public company following admission to the UK PLUS stock exchange and subsequently moved to AIM in July 2010.